Dr. Miyoung Yoon is a Managing Scientist with ToxStrategies and is based in Research Triangle Park, NC. She is leading the company’s efforts to advance chemical safety science by combining in vitro and computational tools. Dr. Yoon helps our clients translate new streams of in vitro and in silico kinetics and toxicity data to estimate human safe exposure levels for risk-based assessment. This expertise supports early product development, regulatory submissions, and research and development activities, to enable a proactive response to the changing regulatory environment. Her expertise has served clients in multiple business sectors, including the agrichemical, cosmetics, consumer products, and pharmaceutical industries, as well as various industry trade associations.
Dr. Yoon has particular expertise in incorporating metabolism and kinetics into the in vitro, non-animal-based toxicity testing and safety assessment of chemicals and drugs. Her expertise ranges from in vitro metabolism, in vitro biokinetics, and physiologically based pharmacokinetic/biokinetic (PBPK) modeling, to in vitro–to–in vivo extrapolation (IVIVE). Dr. Yoon is an internationally recognized expert in the field of quantitative IVIVE, which is a crucial element of the National Academy of Science’s vision for toxicity testing in the 21st century. Currently, she is focusing on the development of new in vitro metabolism and pharmacokinetic assays and extrapolation modeling (IVIVE) approaches to assist interpretation of cell-based toxicity assay results, using both high-throughput and chemical-specific approaches, in the context of risk and safety assessment of chemicals and drugs in different human populations.
Dr. Yoon’s list of more than 50 publications includes both peer-reviewed articles and book chapters. She is an active contributor to education and training being provided to the toxicology and safety science communities. Her efforts include organizing a series of workshops and continuing education courses on physiologically based pharmacokinetic modeling and its applications, in particular to IVIVE and children’s risk assessment.